Evidence map›Paper›PMID 34675021›Full record

ArticleBMJ open2021

Eliminating hepatitis C on the Balearic Islands, Spain: a protocol for an intervention study to test and link people who use drugs to treatment and care.

Jeffrey V Lazarus, Andrea Herranz, Camila A Picchio, Marcela Villota-Rivas, Antonia Rodríguez, Juan Manuel Alonso, Albert Moratinos, Antonella Perrotta, Elisabet Tegeo, Francisca Bibiloni and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Implementing a new HCV model of care for people who use drugs.JHEP reports : innovation in hepatology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Jeffrey V LazarusBarcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain jeffrey.lazarus@isglobal.org.ORCID 0000-0001-9618-2299
Andrea HerranzBarcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.
Camila A PicchioBarcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.ORCID 0000-0002-0321-662X
Marcela Villota-RivasBarcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.
Antonia RodríguezServicio médico, Centro Penitenciario de Mallorca, Palma de Mallorca, Spain.
Juan Manuel AlonsoUnitat de Conductes Addictives 4 (IBSalut), Palma de Mallorca, Spain.
Albert MoratinosUnitat de Conductes Addictives, Institut d'Afers Socials Mallorquí (IMAS), Palma de Mallorca, Spain.
Antonella PerrottaSector mèdic, Projecte Home Balears, Illes Balears, Spain.
Elisabet TegeoSector mèdic, Projecte Home Balears, Illes Balears, Spain.
Francisca BibiloniPla d'addiccions i drogodependències de les Illes Balears (PADIB), Conselleria de Salut i Consum, Govern de les Illes Balears, Spain.
Maria Buti *Liver Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain.ORCID 0000-0002-0732-3078
Àngels Vilella *Department of Gastroenterology, Hospital Universitari Son Llàtzer, Palma de Mallorca, Spain.
Barcelona Institute for Global Health · ESGovern de les Illes Balears · ESCabildo de La Palma · ESFundació Balear d'Innovació i Tecnologia · ESHospital Son Llatzer · ESInstituto de Salud Carlos III · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe hepatitis C virus (HCV) is a highly infectious and deadly disease, affecting some 58 million people worldwide. Of the 1.13 million people living in the Balearic Islands, Spain, about 1350 individuals have untreated HCV. Of these, about 1120 (83%) are estimated to be people who use drugs (PWUD), who are one of the key at-risk groups for HCV infection globally. Carrying out micro-elimination approaches focused on this population is crucial to achieve the WHO goal of eliminating HCV by 2030. Thus, the primary objective of this study is to validate a model of care that simplifies the screening and linkage to HCV care pathways for PWUD on the Balearic Islands. METHODS AND ANALYSIS: This intervention study will be implemented across 17 sites, in 4 different settings: addiction service centres (n=12), non-governmental organisation centres (n=3), a mobile methadone unit and a prison, with an estimated 3725 participants. Together with the healthcare staff at each centre, the intervention protocols will be adapted, focusing on four phases: recruitment and testing; linkage to care; treatment for those who test positive; and monitoring of sustained virological response 12 weeks after treatment and reinfection. The primary outcomes will be the number of tested and treated individuals and the secondary outcomes will include individuals lost at each step in the cascade of care. Descriptive analysis and multivariable logistic regression of the data will be undertaken. ETHICS AND DISSEMINATION: The Hospital Clínic Barcelona, Spain, Ethics Committee approved this study on 18 February 2021 (HCB/2020/2018). Findings will be disseminated through peer-reviewed publications, conference presentations and social media. The results of this study could provide a model for targeting PWUD for HCV testing and treatment in the rest of Spain and in other settings, helping to achieve the WHO HCV elimination goal.

Indexed as

Hepatitis CPharmaceutical PreparationsSubstance Abuse, IntravenousAntiviral AgentsHepacivirusHumansSpainWorld Health OrganizationAntiviral AgentsPharmaceutical Preparationshepatologypublic healthvirology

Identifiers

PMID34675021
PMCPMC8532552
OpenAlexW3207849623

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.